WO2002004516A3 - Verwendungen des hitzeschockproteins gp96 - Google Patents
Verwendungen des hitzeschockproteins gp96 Download PDFInfo
- Publication number
- WO2002004516A3 WO2002004516A3 PCT/EP2001/007864 EP0107864W WO0204516A3 WO 2002004516 A3 WO2002004516 A3 WO 2002004516A3 EP 0107864 W EP0107864 W EP 0107864W WO 0204516 A3 WO0204516 A3 WO 0204516A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- heat shock
- shock protein
- apcs
- antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001285814A AU2001285814A1 (en) | 2000-07-10 | 2001-07-09 | Use of the heat shock protein gp96 |
CA002415434A CA2415434A1 (en) | 2000-07-10 | 2001-07-09 | Use of the heat shock protein gp96 |
EP01965092A EP1299113A2 (de) | 2000-07-10 | 2001-07-09 | Verwendungen des hitzeschockproteins gp96 |
US10/338,115 US20030175249A1 (en) | 2000-07-10 | 2003-01-07 | Uses of the heat shock protein gp96 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10033245A DE10033245A1 (de) | 2000-07-10 | 2000-07-10 | Verwendungen des Hitzeschockproteins gp96 |
DE10033245.5 | 2000-07-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/338,115 Continuation US20030175249A1 (en) | 2000-07-10 | 2003-01-07 | Uses of the heat shock protein gp96 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002004516A2 WO2002004516A2 (de) | 2002-01-17 |
WO2002004516A3 true WO2002004516A3 (de) | 2002-07-18 |
Family
ID=7648253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/007864 WO2002004516A2 (de) | 2000-07-10 | 2001-07-09 | Verwendungen des hitzeschockproteins gp96 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030175249A1 (de) |
EP (1) | EP1299113A2 (de) |
AU (1) | AU2001285814A1 (de) |
CA (1) | CA2415434A1 (de) |
DE (1) | DE10033245A1 (de) |
WO (1) | WO2002004516A2 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPD20070252A1 (it) * | 2007-07-24 | 2009-01-25 | Primiero Paolo | Complessi di grp94 ed immunoglobuline g umane |
WO2018049130A1 (en) * | 2016-09-09 | 2018-03-15 | The General Hospital Corporation | Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
WO2000019828A1 (en) * | 1998-10-05 | 2000-04-13 | University Of Connecticut Health Center | METHODS FOR GENERATING ANTIGEN-REACTIVE T CELLS $i(IN VITRO) |
-
2000
- 2000-07-10 DE DE10033245A patent/DE10033245A1/de not_active Withdrawn
-
2001
- 2001-07-09 EP EP01965092A patent/EP1299113A2/de not_active Withdrawn
- 2001-07-09 CA CA002415434A patent/CA2415434A1/en not_active Abandoned
- 2001-07-09 WO PCT/EP2001/007864 patent/WO2002004516A2/de not_active Application Discontinuation
- 2001-07-09 AU AU2001285814A patent/AU2001285814A1/en not_active Abandoned
-
2003
- 2003-01-07 US US10/338,115 patent/US20030175249A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
WO2000019828A1 (en) * | 1998-10-05 | 2000-04-13 | University Of Connecticut Health Center | METHODS FOR GENERATING ANTIGEN-REACTIVE T CELLS $i(IN VITRO) |
Non-Patent Citations (2)
Title |
---|
SINGH-JASUJA HARPREET ET AL: "Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 11, 5 June 2000 (2000-06-05), pages 1965 - 1974, XP002198240, ISSN: 0022-1007 * |
SINGH-JASUJA HARPREET ET AL: "The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 30, no. 8, August 2000 (2000-08-01), pages 2211 - 2215, XP002174948, ISSN: 0014-2980 * |
Also Published As
Publication number | Publication date |
---|---|
CA2415434A1 (en) | 2002-01-17 |
AU2001285814A1 (en) | 2002-01-21 |
DE10033245A1 (de) | 2002-01-24 |
EP1299113A2 (de) | 2003-04-09 |
WO2002004516A2 (de) | 2002-01-17 |
US20030175249A1 (en) | 2003-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
EP2246067A3 (de) | Verfahren zur Auslösung, Verstärkung und Aufrechterhaltung von Immunreaktionen gegen eingeschränkte Klasse-I-MHC-epitope für prophylaktische oder therapeutische Zwecke | |
WO2002012341A3 (en) | Her-2/neu fusion proteins | |
IL144371A0 (en) | Her-2/neu fusion proteins | |
CA2259140A1 (en) | Method of activating dendritic cells | |
WO2003045427A3 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
WO2001051633A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
AU9312198A (en) | Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer | |
CA2185470A1 (en) | Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes | |
WO1998013500A3 (en) | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines | |
ATE389397T1 (de) | Adjuvante zusammensetzungen | |
UA85365C2 (ru) | Продукт конъюгирования цитокина для использования в противораковой терапии | |
WO2002078516A3 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
WO2002024739A3 (en) | Spas-1 cancer antigen | |
WO2006081576A3 (en) | Immunologically active compositions | |
WO2001040469A3 (en) | Tick antigens and compositions and methods comprising them | |
WO1999032634A3 (en) | Compositions derived from mycobacterium vaccae and methods for their use | |
WO2005026192A3 (en) | Hpv cd8+ t-cell epitopes | |
WO2002004516A3 (de) | Verwendungen des hitzeschockproteins gp96 | |
WO2000061766A3 (en) | Telomerase-specific cancer vaccine | |
WO2000063406A3 (en) | Adenoviral vectors having nucleic acids encoding immunomodulatory molecules | |
WO2003093298A3 (en) | Immunogenic peptides | |
WO2001090152A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
WO2001036453A3 (en) | Ny-eso-1 nanopeptide derivatives, and uses thereof | |
EP2270171A3 (de) | Haemophilus influenzae-Antigene und entsprechende DNA-Fragmente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10338115 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2415434 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001285814 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001965092 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001965092 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001965092 Country of ref document: EP |